You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
神威藥業(02877.HK)公佈中期業績 線上銷售大增212% 中期息11分
格隆匯 08-28 12:52

格隆匯8月28日丨神威藥業(02877.HK)公告,截至2020年6月30日止6個月,公司實現營業收入11.9億元人民幣,期間淨利潤達2.54億元,宣派每股中期股息人民幣11分。

期間毛利率為73.6%,比去年同期71.3%略有上升,主要是由於較高毛利率的口服類產品利潤貢獻比例持續增加。

儘管在疫情下個別產品啟動上線進度受到影響,集團互聯網數字營銷2020年上半年完成了線上銷售人民幣3,350萬,比去年同期增長212.0%。集團互聯網數字營銷事業部年內另一個重點發展是開拓創新試點社羣營銷業務,快速佈局運動健康營銷推廣渠道。依託集團的運動健康產品,迅速搭建社羣營運團隊,以社羣營銷探索新的線上增長模式。除繼續加大與主流電商平台合作外,將增強結合利用大數據為基礎的市場拓展以推動數字化營銷。

集團中藥配方顆粒銷售團隊於2020年上半年新增河北省醫院客户共計68家,新開基層基層醫療機構客户共計435家。期內新增醫院及診所終端銷售佔比13.1%,原有醫院及診所終端銷售佔比86.9%。上半年雲南省新增客户共計41家,主要為基層醫療機構,二級及以上的醫院客户亦在積極開拓中。集團中藥配方顆粒在雲南省的業務發展將成另一個主要增長點。

截至2020年6月底,集團共有超過110個常規生產產品,分佈17個治療領域,其中19個為集團獨家產品,18個被列入國家基本藥物目錄,共有23種產品獲被納入國家低價藥品清單目錄、16種產品被納入省低價藥品清單目錄,及3種產品被納入急救藥品目錄內。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account